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Background: Systemic sclerosis (SSc) is characterised by multi-organ tissue fibrosis including the myocardium.
Diffuse myocardial fibrosis can be detected non-invasively by T1 and extracellular volume (ECV) quantification, while
focal myocardial inflammation and fibrosis may be detected by T2-weighted and late gadolinium enhancement
(LGE), respectively, using cardiovascular magnetic resonance (CMR). We hypothesised that multiparametric CMR can
detect subclinical myocardial involvement in patients with SSc.
Methods: 19 SSc patients (18 female, mean age 55 ± 10 years) and 20 controls (19 female, mean age 56 ± 8 years)
without overt cardiovascular disease underwent CMR at 1.5T, including cine, tagging, T1-mapping, T2-weighted,
LGE imaging and ECV quantification.
Results: Focal fibrosis on LGE was found in 10 SSc patients (53%) but none of controls. SSc patients also had areas
of myocardial oedema on T2-weighted imaging (median 13 vs. 0% in controls). SSc patients had significantly higher
native myocardial T1 values (1007 ± 29 vs. 958 ± 20 ms, p < 0.001), larger areas of myocardial involvement by native
T1 >990 ms (median 52 vs. 3% in controls) and expansion of ECV (35.4 ± 4.8 vs. 27.6 ± 2.5%, p < 0.001), likely
representing a combination of low-grade inflammation and diffuse myocardial fibrosis. Regardless of any regional
fibrosis, native T1 and ECV were significantly elevated in SSc and correlated with disease activity and severity.
Although biventricular size and global function were preserved, there was impairment in the peak systolic
circumferential strain (-16.8 ± 1.6 vs. -18.6 ± 1.0, p < 0.001) and peak diastolic strain rate (83 ± 26 vs. 114 ± 16 s-1,
p < 0.001) in SSc, which inversely correlated with diffuse myocardial fibrosis indices.
Conclusions: Cardiac involvement is common in SSc even in the absence of cardiac symptoms, and includes
chronic myocardial inflammation as well as focal and diffuse myocardial fibrosis. Myocardial abnormalities detected
on CMR were associated with impaired strain parameters, as well as disease activity and severity in SSc patients.
CMR may be useful in future in the study of treatments aimed at preventing or reducing adverse myocardial
processes in SSc.
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Systemic sclerosis (SSc) is an autoimmune connective
tissue disorder characterised by vascular dysfunction and
multi-organ fibrosis. The heart is one of the major
organs commonly involved in SSc, with an estimated
clinical prevalence of 15-35% [1]. Cardiovascular disease
(CVD) in SSc may be direct (cardiac fibrosis, myocardi-
tis, dilated cardiomyopathy, cardiac failure, premature
coronary artery disease, conduction system abnorma-
lities, valvular disease and pericardial disease) or indirect
(pulmonary hypertension and renal crisis) [2,3]. In the
majority of SSc patients, however, CVD often remains
subclinical [4]. SSc patients with apparent cardiovascular
clinical features are at greater risk of deterioration and
premature cardiovascular death [5]. Therefore, early
detection and monitoring of myocardial and vascular
involvement is a crucial aspect of management [6].
Diffuse myocardial fibrosis is the pathological hallmark
of cardiovascular involvement in SSc, reported in up to
80% of cases in autopsy studies [7], and is thought to rep-
resent the final common expression of ‘contraction band
necrosis’, recurrent episodes of ischaemia-reperfusion in-
jury, microvascular dysfunction and chronic myocardial
inflammation [4,8,9]. However, myocardial inflammation
and diffuse fibrosis are difficult to detect clinically, and
endomyocardial biopsy is limited by sampling error, low
diagnostic sensitivity and its invasive nature [10].
Cardiovascular magnetic resonance (CMR) can non-
invasively detect myocardial inflammation and fibrosis.
T2-weighted imaging can identify areas of myocardial
oedema, and late gadolinium enhancement (LGE) im-
aging can identify areas of focal fibrosis in patients with
SSc [11,12]. However, conventional T2-weighted imaging
only has modest sensitivity in detecting myocardial
oedema [13,14], especially in mild cases, and LGE is sub-
optimal as a technique to detect diffuse myocardial fi-
brosis [15,16]. Recently, T1 mapping and extracellular
volume (ECV) quantification have emerged as novel
methods that can overcome both of these limitations
and are promising to detect subtle forms of myocardial
inflammation and diffuse myocardial fibrosis. T1 map-
ping is highly sensitive to myocardial water and is superior
to T2-weighted imaging in detecting myocardial oedema
[14,17]. T1 mapping and ECV measurements can also act
as surrogates for diffuse fibrosis [18,19] on the premise of
detecting myocardial water in the expanded interstitial
space, and have been shown to correlate well with histo-
logical indices of myocardial fibrosis in various clinical
contexts [20,21].
We therefore hypothesised that T1 and ECV quantifi-
cation would reveal subclinical myocardial involvement
in asymptomatic SSc patients with no known cardiovas-
cular involvement when compared to controls of similar
age and sex. We also sought to investigate the relationshipbetween myocardial findings on CMR and indices of SSc
activity, severity and chronicity, and early signs of myocar-
dial dysfunction.
Methods
Study population
This was a prospective study enrolling unselected pa-
tients with SSc (n = 19), without any known CVD. Pa-
tients were recruited from 5 hospitals in the Thames
Valley, United Kingdom (John Radcliffe Hospital, Oxford;
Nuffield Orthopaedic Centre, Oxford; Great Western
Hospital, Swindon; Royal Berkshire Hospital, Reading; and
Stoke Mandeville Hospital, Aylesbury) between January
2011 and December 2012. The SSc patients were between
the ages of 18 and 65 years, and were diagnosed with SSc
using the 1980 American College of Rheumatology cri-
teria [22]. Exclusion criteria included inability to tol-
erate CMR, contraindications to CMR, non-sinus rhythm,
known heart disease (previous myocardial infarction, pre-
vious myocarditis, heart failure, arrhythmia on 12-lead
ECG and medical history or other chronic cardiac condi-
tion), renal impairment (estimated glomerular filtration
rate below 30 mL/min), impaired liver function (alanine
aminotransferase greater than twice the upper limit of
normal), a female who was pregnant, lactating or planning
a pregnancy, and known hypersensitivity to gadolinium.
Age- and sex-matched healthy individuals (n = 20) with
no cardiac history, not on cardiovascular medications
(except 3 on hormone replacement therapy) and with
a normal ECG were used for comparison. All subjects
gave written informed consent to participate in the
study. Ethical approval was granted for all study pro-
cedures by the Oxford Research Ethics Committee (REC
Ref 10/H0606/32).
CMR
CMR studies were performed using a single 1.5 T MR
system (Avanto, Siemens Healthcare, Germany). A 32-
channel phased-array chest coil was used for all data ac-
quisition, except for STIR imaging, for which the body
coil was used. A complete stack of short axis images
were obtained during breath hold and cardiac gating for
cine, precontrast (native) T1 mapping, T2-weighted and
LGE imaging. T1 mapping was performed using the
ShMOLLI (Shortened Modified Look-Locker Inversion
Recovery) sequence [19], and T2 weighted-CMR was
performed with the black blood short-Tau inversion re-
covery (STIR) sequence as previously published [23].
Tagged cine CMR was acquired with an ECG-triggered
segmented k-space gradient echo sequence with spatial
modulation of magnetisation (SPAMM) in orthogonal
planes [24]. Three short axis (basal, mid-ventricular and
apical) scans and a single long axis (horizontal) scan
were obtained for tagging. T2-weighted and cine tagged
Ntusi et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:21 Page 3 of 12
http://jcmr-online.com/content/16/1/21images were acquired before administration of contrast
agent. LGE imaging was performed as previously de-
scribed [25], using a T1-weighted phase-sensitive inver-
sion recovery sequence about 8 minutes after intravenous
administration of contrast agent (Gadoterate meglumine–
Gd-DOTA, Dotarem, Guerbet LLC, France; 0.15 mmol/kg
body weight). A single mid-ventricular short axis slice was
acquired for postcontrast T1 maps at 1, 2, 3, 4, 8, 15
and 20 minutes after the administration of contrast
(Gd-DOTA). Typical imaging parameters for the se-
quences used were as previously published [14].
CMR image analysis
All CMR images and maps were analysed offline in a
blinded fashion.
Cine images
Analysis of left ventricular ejection fraction was per-
formed using Argus software (Version VB17, 2011, Sie-
mens Medical Solutions). Left ventricular (LV) short axis
epicardial and endocardial borders were manually con-
toured at end-diastole and end-systole. LV end systolic
(LVESV) and end diastolic (LVEDV) volumes were used
to calculate stroke volume (SV) and ejection fraction
(EF) – (EF = SV/EDV). Myocardial mass was also calcu-
lated by subtracting the endocardial volume from the
epicardial volume, based on prior knowledge of myo-
cardial specific gravity (1.05 g/cm3). Left atrial diameter
was measured in the LV outflow tract (3-chamber) view.
Tagged cine images
Post-processing and semi-automated analysis was per-
formed using CIM software (CIMTag2D, Auckland, New
Zealand) by aligning a grid to the myocardial tagging
planes in end-diastole. End-systole was determined visually,
and tags are adjusted at each frame through the cardiac
cycle. From the mid-short axis slice, peak circumferential
systolic strain and peak diastolic strain rate were derived.
STIR images
Quantitative analysis was performed by comparing the LV
myocardium in short axis against adjacent skeletal muscle
in the same slice, verified on a corresponding SSFP image.
The T2 signal intensity (SI) ratio was calculated as T2
SImyocardium:skeletal = SImyocardium/SIskeletal muscle, as previ-
ously published [23]. Myocardial oedema was diagnosed
when myocardial T2 SI ratio is > 1.9. Care was taken to
exclude non-suppressed blood pool signal due to slow-
flow adjacent to the subendocardium and to avoid using
areas with abnormally low signal for normalisation.
LGE images
Images were evaluated qualitatively for the presence or
absence, pattern (subendocardial, midwall, subepicardial,transmural) and regional distribution of LGE areas by
three observers, each with at least 4 years of CMR ex-
perience. The detection of LGE was made by consensus
of all 3 observers. In addition, endocardial and epicardial
regions of interest (ROI) were manually contoured in the
LGE images, together with a reference ROI in the anterior
LV wall without visual LGE, and focal areas of LGE were
defined quantitatively as those with SI ≥ 2.0 standard devi-
ations above the mean SI of normal myocardium.
T1-maps
Analysis of T1 mapping was performed as previously de-
scribed [19]. Briefly, after T1maps were generated, short
axis images were manually contoured using in-house
software MC-ROI (programmed by SKP in Interactive
Data Language, version 6.1, Exelis Visual Information
Solutions, Boulder, Colorado, USA) to outline the endo-
and epicardium, and then divided into 6 segments per
slice using the anterior right ventricular RV-LV insertion
point as reference and for comparing segments amongst
sequences [14].
Consistent with established methods of estimating myo-
cardial ECV using a delayed postcontrast bolus protocol
[26], we measured precontrast and postcontrast myocar-
dial and blood T1 values. The estimation of ECV and
lambda (λ) was based on multipoint regression [27], in-
corporating all available precontrast and postcontrast
points, in order to increase the robustness of the estimates
by increasing number of underlying data points. ECV was
calculated as (1 – haematocrit). We have not observed
any consistent deviations from the linear regression line in
our data (median R = 0.99, interquartile range = 0.99 to
1.00) to support effects of transcytolemmal exchange, in-
dicating that fast exchange effects only contribute less that
0.1% effect on ECV [28]. We also checked that the esti-
mates obtained from the latest postcontrast time (~20 mi-
nutes) did not yield any significant difference both across
all (P > 0.9) and in the most affected subgroup (P = 0.8) to
exclude any potential effects of sub-equilibrium gadoli-
nium redistribution. For calculation of postcontrast T1
values, the postcontrast T1 map acquired at 20 minutes
was utilised.
Areas of myocardial involvement by STIR and precontrast
T1 mapping
Briefly, on dark-blood T2W images, oedema was diag-
nosed when myocardial T2 SI is ≥ 1.9 compared to that
of skeletal muscle [13]; on T1 maps, acute myocardial in-
jury was diagnosed when T1 was > 990 ms, as previously
published for the objective detection of acute myocardial
oedema [17]. For all quantitative analyses of T2-weighted
and T1 map images, only regions of myocardium with a
contiguous area of ≥40 mm2 above the specified thresh-
olds were considered relevant. This corresponds to 10
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currently proposed recommendations [13], to reduce the
detection of noise as positive findings. To calculate the ex-
tent of myocardial involvement in a subject detected by
the tissue characterisation techniques, the percentage of
abnormal myocardium as defined above was determined
for each segment and then averaged for that subject.
Echocardiography
Two-dimensional, M-mode and Doppler echocardio-
grams were acquired using a Toshiba Artida 4D system
(Toshiba Medical Systems Corporation, Tokyo, Japan).
Images were acquired with the patients in the left lateral
decubitus position. Primary measurements of mitral in-
flow included the peak early filling (E-wave) and late dia-
stolic filling (A-wave) velocities, the E/A ratio, deceleration
time (DT) of early filling velocity, which were derived by
placing the cursor of the pulsed wave Doppler in the LV,
above the tips of the mitral valve, to display the onset of
mitral inflow, using a 5 MHz transducer. The passive LV
filling (E’-wave) was measured from the pulsed wave tissue
Doppler of the mitral septal annular velocity. Right ven-
tricular systolic pressure was based on measurement of
maximal tricuspid regurgitation velocity and applying the
modified Bernoulli equation before addition of the esti-
mated right atrial pressure (5 mmHg).
SSc disease activity and severity
Disease activity was assessed using the Valentini disease
activity index (VDAI) of the European Scleroderma
Study Group criteria for disease activity in SSc [29], which
incorporates skin changes, digital necrosis, lung function
tests, ESR and serum complement.
SSc patients were classified as having either diffuse
(n = 10) or limited cutaneous SSc (n = 9). The sever-
ity of skin fibrosis was quantified using the modified
Rodnan skin score (mRSS) [30], a measure of SSc disease
severity and activity based on skin thickness at 17 anato-
mical sites.
Statistical analysis
Normality of data was tested using the Kolmogorov-
Smirnov test. Normally distributed data are presented as
mean ± standard deviation (SD) or, where highly skewed,
as median (interquartile range); non-parametric data are
presented as numbers (percentages). The chi-square test
or Fischer’s exact test was used to compare dichotomous
data. The unpaired Student t-test (when normally distri-
buted) or Mann-Whitney U test (for non-parametric data)
was used to compare continuous variables between SSc pa-
tients and controls, as appropriate. Post-hoc Bonferroni
correction was used to explore whether there were differ-
ences between the SSc patients and controls. Any segmen-
tal data were averaged on a per-subject basis before groupcomparisons to control for clustering of segments within
each subject. Bivariate correlations were assessed using
the Pearson R or Spearman RS coefficient, as appropriate.
All statistical tests were two-tailed and a p-value of less
than 0.05 was considered statistically significant. All ana-
lysis was performed using SPSS version 20 (IBM, Armonk,
New York, USA).
Results
Baseline characteristics of the patient population
The SSc patients were well-matched with controls for
age, sex and comorbidities and only a small minority of
patients were on regular disease modifying anti-rheumatic
drugs (Table 1). Most patients had been diagnosed with
SSc for more than a decade (median disease duration
14 years, IQR 5-19). In SSc patients, the VDAI and the
mRSS were 4 ± 2 and 20 ± 6, respectively, indicating the
presence of active disease and organ involvement in the
group overall.
Myocardial structure and function
There was no significant difference in LV size, mass and
ejection fraction between SSc patients and controls
(Table 2). Despite normal global LV systolic function on
cine imaging, peak systolic circumferential strain by
tagged CMR was impaired in SSc patients compared to
controls (-16.8 ± 1.6 vs. -18.6 ± 1.0, p < 0.001), indicating
an abnormality in regional function and myocardial de-
formation characteristics. The left atrial (LA) diameter was
larger in SSc patients (37 ± 6 vs. 28 ± 5 mm, p < 0.001),
likely due to diastolic dysfunction, as demonstrated by the
reduced peak diastolic strain rate in SSc patients (83 ± 26
vs. 114 ± 16 s-1, p < 0.001) compared to controls. Evidence
of impaired diastolic function was also confirmed on echo-
cardiographic assessment, which showed abnormal rela-
xation indices in SSc patients (E/A: 1.8 ± 0.5 vs. 1.4 ± 0.2,
p = 0.039; and E/E’: 11 ± 4 vs. 7 ± 1, p = 0.006).
We found no difference in RV size and global systolic
function between SSc patients and controls. While right
ventricular systolic pressures were higher in the SSc
patients (24 ± 5 vs. 16 ± 4 mmHg, p < 0.001), they were
within normal limits for all study subjects, excluding
the presence of significant pulmonary hypertension in
this cohort.
Patchy fibrosis (LGE imaging)
Confirming previously published data, we found in-
creased incidence of LGE in SSc patients compared to
matched controls (53% vs. 0%), as shown in Table 2. All
had a non-ischemic pattern of fibrosis, with about a third
of SSc patients demonstrating patchy mid-wall LGE in the
basal inferolateral wall; and 21% in the septum (Figure 1).
No patient had any previous myocardial infarction
(isolated LGE involving the subendocardium). Overall,
Table 1 Baseline characteristics of the study population
Controls SSc P
valueN = 20 N = 19
Demographic and clinical features and co-morbidity
Female sex, n (%) 19 (95) 18 (95) 0.74
Age, years 56 ± 8 55 ± 10 0.64
Current smokers, n (%) 0 (0) 2 (11) -
Hypertension, n (%) 2 (10) 4 (21) 0.41
Diabetes, n (%) 0 (0) 0 (0) –
Hyperlipidaemia, n (%) 4 (20) 3 (16) 0.73
Obesity, n (%) 2 (10) 4 (21) 0.34
BMI, kg/m2 25 ± 4 27 ± 7 0.23
Medical therapy
Methotrexate, n (%) None 5 (26) –
Prednisolone, n (%) None 2 (11) –
Azathioprine, n (%) None 1 (5) –
Chloroquine, n (%) None 1 (5) –
Leflunomide, n (%) None 1 (5) –
Sulfasalazine, n (%) None 0 (0) –
HRT, n (%) 3 (15) 4 (21) 0.62
NSAID, n (%) None 3 (16) –
Duration of DMARDs, years (median, IQR) N/A 2 (1-8) –
Duration of NSAIDs, years (median, IQR) N/A 1 (1-4) –
Disease activity and chronicity indices
SSc VDAI N/A 4 ± 2 –
ESR, mm/hr (median, IQR) N/A 11 (3-18) –
CRP, mg/L (median, IQR) 3 (1-4) 5 (2-8) 0.01
Hemoglobin (g/L) 13 ± 1 12 ± 1 0.05
Haematocrit (%) 41 ± 11 34 ± 9 0.001
Creatinine (μmol/L) N/A 67 ± 10 –
Duration of SSc, years (median, IRQ) N/A 14 (5-19) –
mRSS N/A 20 ± 6 –
Limited/diffuse cutaneous SSc, n (%) N/A 10/9 –
Anti-centromere antibodies, n (%) N/A 8 (42) –
Anti-topoisomerase 1 antibodies, n (%) N/A 5 (26) –
Continuous data are mean ± SD unless otherwise indicated.
AID, Autoimmune disease; BMI, Body mass index; CAD, Coronary artery disease;
CRP, C-reactive protein; DMARD, Disease modifying anti-rheumatic drug; ESR,
Erythrocyte sedimentation rate; HRT, Hormone replacement therapy; mRSS,
Modified Rodnan skin score; NSAID, Non-steroidal anti-inflammatory drug; SSc,
Systemic sclerosis; VDAI, Valentini disease activity index of the European
Scleroderma Study Group.
Table 2 CMR findings
Controls SSc P
valueN = 20 N = 19
LVEDV indexed, mL/m2 77 ± 16 69 ± 11 0.08
LVESV indexed, mL/m2 21 ± 5 18 ± 5 0.06
LVEF, % 73 ± 5 74 ± 6 0.52
LV Mass indexed, g/m2 52 ± 11 51 ± 8 0.74
LA size, mm 28 ± 5 37 ± 6 <0.001
RVEDV indexed, mL/m2 85 ± 19 77 ± 12 0.32
RVESV indexed, mL/m2 28 ± 7 25 ± 7 0.06
RVEF, % 67 ± 4 67 ± 6 0.14
Mid SA circumferential strain -18.6 ± 1.0 -16.8 ± 1.6 <0.001
Peak diastolic circumferential
strain rate (s-1)
114 ± 16 83 ± 26 <0.001
Presence of LGE (%) 0 10 (53) –
Volume fraction of LGE > 2SD (%) 0 4 (2-5) –
Global myocardial T2 SI Ratio 1.6 ± 0.5 1.7 ± 0.4 0.66
Volume fraction of oedema by T2 (%) 0 13 (0-21) –
Average myocardial T1, ms 958 ± 20 1007 ± 29 <0.001
Volume fraction of T1 > 990 ms (%) 3 (1-9) 52 (40-70) <0.001
Postcontrast T1, ms 454 ± 29 457 ± 50 0.9
λ 0.44 ± 0.15 0.56 ± 0.23 0.02
ECV (%) 27.6 ± 2.5 35.4 ± 4.8 <0.001
Continuous data are mean ± SD unless otherwise indicated.
LA, Left atrium; LGE, Late gadolinium enhancement; LV, Left ventricle/
ventricular; LVEDV, Left ventricular end-diastolic volume; LVEF, Left ventricular
ejection fraction; LVESV, Left ventricular end-systolic volume; RVEDV; Right
ventricular end-diastolic volume; RVEF, Right ventricular ejection fraction;
RVESD, Right ventricular end-systolic volume; SA, Short axis; SSc, Systemic
sclerosis; STIR, Short Tau inversion recovery.
For postcontrast T1, λ and ECV, the number of SSc patients included in the
analysis is 14 rather than 19.
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(3.8 ± 0.4% of total LV mass).
Myocardial oedema (T2-weighted CMR)
On conventional dark-blood T2-weighted imaging, while
there was no significant difference in the overall global
myocardial T2 SI ratio in SSc patients compared tocontrols (1.7 ± 0.4 vs. 1.6 ± 0.5, p = 0.66), SSc patients
had significantly more areas of focal myocardial oedema
within the left ventricle (median 13% vs. 0% in controls;
p < 0.001).
T1 mapping and extracellular volume (ECV) quantification
Native T1 mapping was performed in all SSc patients;
and postcontrast T1 mapping was done in 14 of the 19
SSC patients, as 5 patients were not consented for gado-
linium. SSc patients had significantly higher average myo-
cardial T1 values (1007 ± 29 vs. 958 ± 20 ms, p < 0.001)
and larger areas of myocardial involvement detected
by native T1 mapping (median 52% vs. 3% in controls,
p < 0.001). SSc patients also had significantly higher λ
(0.56 ± 0.23 vs. 0.44 ± 0.15, p = 0.02) and expanded ECV
(35.4 ± 4.8 vs. 27.6 ± 2.5%, p < 0.001; Figure 2).
Postcontrast T1 and λ values were found to be less
good as measures of diffuse myocardial fibrosis. There
was no difference in postcontrast T1 values between SSc
Figure 1 Representative examples of pre- and postcontrast T1 maps with corresponding LGE images in SSc and controls. Top panel
(A): normal control with no LGE, native T1 947 ms, postcontrast T1 514 ms, ECV 26.7%; Second panel (B): SSc patient with linear septal and
patchy basal inferolateral LGE, native T1 1001 ms; postcontrast T1 453 ms; ECV 33.7%; Third panel (C): SSc patient with small areas of mid-wall
inferior and lateral LGE, native T1 988 ms, postcontrast T1 439 ms, ECV 36.1%; Fourth panel (D): SSc patient with no LGE, native T1 1017 ms,
postcontrast T1 421 ms, ECV 39.4%. LGE, late gadolinium enhancement. Note the scale change between precontrast and postcontrast T1 maps.
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457 ± 50 vs. 454 ± 29 ms, p = 0.9). Also, there was no dif-
ference in postcontrast T1 values between controls and
SSc patients with LGE, despite the significant differences
in native T1 and ECV. Importantly, between SSc patients
without LGE and SSc patients with LGE, there was no
difference in native T1, postcontrast T1, λ, and ECV, in-
dicating that the increase in ECV was not driven by the
presence of LGE (Table 3).
When SSc patients were stratified according to limited
cutaneous or diffuse SSc, only native T1 mapping and ECV
quantification were able to further differentiate the twosubgroups according to myocardial involvement (Table 4):
patients with diffuse SSc had higher native T1 values
(1011 ± 24 vs. 1002 ± 32 ms, p = 0.01), larger areas of
myocardial involvement by native T1 mapping (median
63% vs. 45%, p < 0.001) and larger ECV (37 ± 4 vs. 33 ± 5%,
p = 0.002), supporting previous reports of greater extent of
diffuse fibrosis affecting multiple organs in SSc patients
with diffuse cutaneous involvement [7]. However, such a
small difference in native T1 and ECV values may not per-
mit diagnosis in individual patients. Other CMR tissue
characteristics showed no significant difference between
the two groups.
Figure 2 Myocardial T1 and extracellular volume (ECV)
quantification in SSc patients and normal controls. ECV,
extracellular volume, SSc, systemic sclerosis. A, Median T1 area
>990 ms in SSc and controls (horizontal line indicates median, box
indicates 25th and 75th centiles); B, Mean ECV values in SSc and
controls (error bars indicate 95% confidence interval).
Table 3 Measures of subclinical myocardial involvement
by T1 mapping and ECV in SSc patients with and without
LGE
SSc without
LGE
SSc with
LGE
P
value
N = 9 N = 10
Volume fraction of LGE > 2SD (%) 0 6 (3-9) –
Precontrast T1 (ms) 1007 ± 36 1006 ± 17 0.99
Volume fraction of T1 > 990 ms (%) 55 (48-78) 51 (39-73) 0.78
Postcontrast T1 (ms)* 470 ± 69 443 ± 12 0.57
λ 0.52 ± 0.21 0.62 ± 0.23 0.13
ECV (%) 34 ± 4 37 ± 5 0.18
STIR T2 Ratio 1.7 ± 0.4 1.6 ± 0.3 0.65
Volume fraction of oedema
(T2 STIR SI >1.9, %)
21 (9-23) 14 (6-17) 0.55
Data are mean ± SD unless otherwise indicated.
*At 20 minutes post gadolinium administration.
λ, Myocardial partition coefficient (Lambda); ECV, Extracellular myocardial
volume; LGE, Late gadolinium enhancement; STIR, Short Tau
inversion recovery.
For postcontrast T1, λ and ECV, the number of SSc patients included in the
analysis is 14 rather than 19.
Table 4 Tissue characterisation in diffuse SSc vs. limited
cutaneous SSc
Diffuse SSc Limited SSc P
value(n = 10) (n = 9)
Volume fraction of LGE > 2SD (%) 4 (1-6) 4 (2-5) 0.981
Volume fraction of oedema
(T2 STIR SI >1.9, %)
12 (2-17) 14 (0-21) 0.939
Volume fraction of T1 > 990 ms (%) 63 (47-78) 45 925-68) <0.001
Precontrast T1 (ms) 1011 ± 24 1002 ± 32 0.010
Postcontrast T1 (ms)* 440 ± 44 466 ± 53 0.367
λ 0.63 ± 0.19 0.49 ± 0.22 0.032
ECV (%) 37 ± 4 33 ± 5 0.002
Data are mean ± SD unless otherwise indicated.
*At 20 minutes post gadolinium administration.
λ, Myocardial partition coefficient (Lambda); ECV, Extracellular myocardial
volume; LGE, Late gadolinium enhancement; STIR, Short Tau
inversion recovery.
For postcontrast T1, λ and ECV, the number of SSc patients included in the
analysis is 14 rather than 19.
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and SSc disease severity
There was significant, moderate correlation of myo-
cardial involvement detected by T1 and ECV to indices of
SSc disease activity and severity: ECV and mRSS (R 0.60,
p = 0.03), ECV and SSc VDAI (RS 0.60, p = 0.04); native
T1 and mRSS (R 0.55, p = 0.02), native T1 and SSc VDAI
(RS 0.55, p = 0.05), native T1 and serum CRP (RS
0.41, p = 0.01) as shown in Figure 3.
The extent of myocardial oedema on T2-weighted
imaging showed significant moderate correlation with
peak systolic strain (RS 0.49, p = 0.001) and diastolic
strain rate (RS -0.46, p = 0.003). Both native T1 and
ECV correlated inversely with peak circumferential sys-
tolic strain (R 0.43, p = 0.006) and diastolic strain rate
(R -0.46, p = 0.003; (Figure 3), suggesting that subclinical
myocardial inflammation and/or diffuse myocardial fibrosisare associated with deformational abnormalities and early
signs of myocardial dysfunction.
Discussion
Our data demonstrated that subclinical myocardial
changes are common in patients with SSc even with ap-
parently normal hearts, which can be detected using
multiparametric CMR. In addition to focal areas of fibrosis
(as detected by LGE), there were also areas of focal myocar-
dial oedema or inflammation (as detected by T2-weighted
imaging). Further, using more sensitive techniques such as
native T1 mapping and ECV quantification, we were able
Figure 3 Correlation of myocardial T1 and ECV to peak circumferential systolic strain and peak diastolic circumferential strain rate.
ECV, extracellular volume. Red dot indicates systemic sclerosis. Blue dot indicates control.
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ment in SSc patients than conventional CMR techniques
can reveal, with SSc patients showing significantly larger
areas of T1 abnormality and expanded ECV, which likely
represent a combination of low grade inflammation and
diffuse myocardial fibrosis that are well-described disease
processes in this cohort. Interestingly, T1-mapping and
ECV quantification were sensitive enough to further stra-
tify myocardial involvement in patients with diffuse SSc
compared to patients with limited cutaneous SSc, with the
former showing significantly larger areas of myocardial T1
abnormality and ECV expansion. Finally, T1 and ECV
measures were associated with subtle myocardial systolic
and diastolic dysfunction. The results of this study suggest
that CMR, particularly T1 and ECV quantification, can be
used for early detection of subclinical myocardial involve-
ment in SSc patients, potentially serving as an earlyscreening tool before overt LV dysfunction or irreversible
myocardial damage occurs.
In historic autopsy studies, diffuse myocardial fibrosis
has been reported as the pathological hallmark of cardio-
vascular involvement in SSc [7,8]. Chronic myocardial in-
flammation together with recurrent ischaemia-reperfusion
injury and microvascular dysfunction are thought to play
a crucial pathophysiological role in the development of
diffuse myocardial fibrosis in SSc [4,8,9] and ultimately
lead to premature cardiovascular mortality, particularly in
those SSc patients with obvious clinical features of heart
disease [5].
Myocardial fibrosis is characterised by excessive de-
position of extracellular matrix proteins, rich in collagen
[31], which ultimately affects myocardial structure and
function, and is associated with impaired systolic and dia-
stolic function, cardiac chamber dilation and arrhythmias
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http://jcmr-online.com/content/16/1/21[32,33]. LGE CMR has been traditionally used to image
regional fibrosis/scarring in the myocardium, based on the
distribution difference of gadolinium in between healthy
and diseased myocardium [15]. The LGE technique has
significant limitations in the assessment of diffuse myocar-
dial fibrosis, where the entire myocardium may be affected
more homogeneously, as occurs with SSc, where there
may be little unaffected myocardium.
Native (precontrast) T1 and ECV mapping are novel
CMR markers that provide a quantitative measure of tis-
sue characterisation without relying on relative signal
comparisons [15]. T1 maps are quantitative, pixel-wise
representations of the T1 relaxation time of the under-
lying myocardial tissue [16]. Increase in native T1 values
is non-specific and can be seen in acute myocardial
oedema, infarction, myocarditis, amyloidosis and diffuse
fibrosis [14,17,34,35]. Postcontrast T1 is dependent on
renal function, body fat distribution, dose of contrast
used, the time delay in measurement after contrast ad-
ministration, but calculating the ECV may minimise
these confounding effects by incorporating the pre- and
post-contrast myocardial and blood T1, partition coeffi-
cient (λ), and adjusting for the haematocrit [36]. In the
absence of oedema or other causes of ECV expansion
such as amyloid and prior myocardial infarction, ECV
increases are considered the best non-invasive surrogate
of diffuse fibrosis [36]. ECV has been validated against
histological collagen proportion [37], and correlates with
poor early cardiovascular outcomes [38]. In this study,
postcontrast T1 values were found to be poor measures
of diffuse fibrosis compared to native T1 and ECV calcu-
lation. Due to the greater variability of this measure-
ment, postcontrast T1 has not been considered as a
preferred method of assessment of diffuse myocardial fi-
brosis in the consensus statement on Myocardial T1
mapping and extracellular volume quantification by the
Society for Cardiovascular Magnetic Resonance (SCMR)
and CMR Working Group of the European Society of
Cardiology [36].
We showed increased native T1 and expanded ECV in
SSc patients without cardiovascular symptoms. It is diffi-
cult to separate how much of the increase in T1 was due
to myocardial inflammation as opposed to diffuse myo-
cardial fibrosis, as both would increase native T1 values
(and hence also ECV). There was a degree of myocardial
oedema as shown by results using T2-weighted imaging,
but the areas of oedema detected are not directly sub-
tractable from areas of abnormality detected by T1, since
these are different techniques with different sensitivities
and specificities for oedema [14]. Native T1 is significantly
more sensitive to myocardial water than conventional T2-
weighted imaging, so areas of oedema detected by T1 are
expected to be larger than those by T2-weighted imaging,
even in just a single disease process. In this cohort, bothmyocardial inflammation and diffuse fibrosis likely co-
exist, and thus, CMR findings (as for any other diagnostic
imaging modality) must be interpreted within the clinical
context. Trying to distinguish between myocardial inflam-
mation and diffuse fibrosis based on imaging alone may
be challenging; the chronicity and relapsing nature of this
disease must be taken into account, which can result in
active myocardial inflammation over existing diffuse fibro-
sis from a previous episode. This is an inherent limitation
that lends a necessary uncertainty, but currently no non-
invasive diagnostic test can achieve this goal and no other
cardiac imaging modality can provide more information
on myocardial tissue characteristics than multiparametric
CMR at this time. In either case, this study shows that
CMR can detect subclinical myocardial involvement in
SSc patients whose hearts would appear otherwise normal
using conventional measures; longitudinal studies follow-
ing disease course and trials assessing response to treat-
ment strategies may shed more light onto the clinical
meaning of T1 and ECV abnormalities in this cohort.
Despite the absence of global functional impairment,
we found impaired peak circumferential LV systolic
strain in SSc patients, in keeping with previous reports
[39]. There was also evidence of diastolic dysfunction
with impaired peak diastolic strain rate, elevated E/E’
and increased left atrial dimensions. Although there
were no major clinical effects on the SSc patients in this
study, the presence of low grade myocardial inflamma-
tion, T1 abnormalities and ECV expansion may not be
benign [16,31-33] and may ultimately lead to focal or
diffuse fibrosis. Certainly, an autopsy study has previ-
ously found focal and interstitial myocardial fibrosis in
SSc patients who had sustained high prevalence of
ventricular arrhythmias and conduction disturbances,
intractable congestive cardiac failure and sudden car-
diac death [8].
T1 and ECV measures both correlated inversely with
peak systolic strain and peak diastolic strain rate in SSc
patients. Several reports (including assessment of focal
myocardial fibrosis by LGE) have confirmed that myo-
cardial fibrosis precedes strain abnormalities and that fi-
brosis is a significant contributor to the pathogenesis of
myocardial relaxation abnormalities [40,41]. Notably, in
hypertensive patients, diastolic function improves after
treatment with aldosterone antagonists, likely reflecting
an antifibrotic effect of these drugs [42]. In diabetes, car-
diac dysfunction, relating to loss of contractile reserve
and abnormal myocardial stiffness, is proportional to the
degree of extracellular matrix deposition [43]. Our find-
ings support the hypothesis that in SSc, adverse myocar-
dial processes may lead to diffuse myocardial fibrosis
and are associated with impairment in myocardial strain.
We have found that both ECV and native T1 are useful
for the assessment of myocardial involvement in SSc. In
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T1 may be used as a surrogate biomarker for myocardial
fibrosis [15,17], if other causes of increased T1 are un-
likely. In this study, ECV and native T1 both correlated
positively with indices of SSc activity and severity, indica-
ting that CMR may be useful in assessing both myocardial
disease severity and activity in SSc. Furthermore, ECV and
native T1 are increased even in SSc patients without focal
fibrosis on LGE imaging, suggesting that these novel CMR
markers provide additional information on tissue cha-
racterisation beyond that achieved by LGE.
Limitations
Our study has several limitations. First, the number of
SSc patients included in this study is small; nevertheless
the control group was well chosen and large significant
differences in the parameters measured have been ob-
served. Second, native myocardial T1 values may in-
crease with myocardial oedema, myocardial infarction,
myocarditis or amyloidosis [17,34,35] and are not spe-
cific for myocardial fibrosis as discussed. Third, T2 map-
ping was not performed in this cohort, which would
have been an interesting comparison; however, T2 map-
ping at the present time seems to have a large inter-
individual variability [43-45], which may not have helped
significantly in distinguishing between myocardial water
from inflammation versus that in an expanded extra-
cellular space. Fourth, besides T1 mapping there is no
other serum or histological test performed to support
the presence of diffuse myocardial fibrosis in our patients;
in this study of early disease in asymptomatic patients,
no myocardial biopsy for histological correlations could
be justified. Finally, we used the VDAI as a measure of dis-
ease activity in SSc. However, several other scores do exist
which could have been used, which all have their own
limitations.
Conclusions
In conclusion, subclinical myocardial involvement is com-
mon in SSc patients without cardiac symptoms, as
measured by T2-weighted imaging, native T1, quanti-
tative LGE and ECV measurement; and likely signifies
a combination of myocardial inflammation and diffuse
fibrosis which correlated with both SSc disease activity and
skin fibrosis severity, as well as with subclinical impairment
of systolic and diastolic strain despite the preserved LV
ejection fraction. These findings support a mechanistic role
for myocardial inflammation and possible diffuse fibrosis
in preclinical as well as advanced SSc disease. The results
of this study highlight key advantages of multiparametric
CMR to track these preclinical changes, which may be
useful in the clinical setting and possibly as surrogate end-
points for therapeutic trials. Finally, our data suggest that
native T1 and ECV measurement may add incrementalinformation to LGE focal fibrosis quantification, and that
focal and diffuse fibrosis may reflect different underlying
pathological processes.
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